[Segye Ilbo] Kim Hyun-soo Stem Cell Clinic Opens, Ushering in an Era of Personalized Treatment

Pamisell Co., Ltd., the developer of the stem cell therapy “Cellgram-AMI,” recently opened the Kim Hyun-soo Stem Cell Clinic, which offers services in stem cell therapy, internal medicine, and plastic surgery.

The Kim Hyun-soo Stem Cell Clinic treats central nervous system disorders such as stroke, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and spinal cord injury, as well as intractable conditions such as acute myocardial infarction, ischemic cardiomyopathy, cirrhosis, and peripheral artery disease.

In addition to general internal medicine, the clinic offers an “internal anti-aging” program aimed at extending lifespan through treatments for organs, tissues, and blood vessels, as well as general plastic surgery procedures and treatment programs in the field of “external anti-aging.”

Director Kim Hyun-soo has built a solid infrastructure in the field of cell therapy over the past decade by operating PamiCell Co., Ltd. and developing stem cell therapies.

Recently, in collaboration with leading global biotech companies and research institutes, the clinic has been developing cell therapies using stem cells and dendritic cells; in particular, it possesses extensive clinical data on brain, spinal cord, heart, liver, and lung diseases.

As the developer of “Cellgram-AMI,” the world’s first stem cell therapy, Dr. Kim’s extensive clinical experience in stem cell therapy serves as the foundation for the Kim Hyun-soo Stem Cell Clinic’s patient-tailored treatments, which are customized to the specific characteristics of various diseases.

In particular, the Kim Hyun-soo Stem Cell Clinic offers a service where medical staff provide consultations directly by phone to patients with intractable diseases. This measure is designed to accommodate patients who find it difficult to make multiple in-person visits. Additionally, following stem cell therapy, the clinic conducts its own post-marketing surveillance (PMS) to monitor patients’ conditions at six-month intervals for three years.

Dr. Kim Hyun-soo, Director of the Kim Hyun-soo Stem Cell Clinic, stated, “We opened this clinic to establish a medical institution dedicated to providing safe and proven personalized treatments tailored to the specific characteristics of each patient’s condition,” adding, “We will take the lead in providing safe, personalized stem cell treatments for patients suffering from intractable diseases.”